The risks of dependence and withdrawal and the potential consequences of untreated anxiety. An analysis of more than 4 million pregnancies found no increased risk of congenital malformations linked to benzodiazepine exposure during the first trimester.
The findings may guide treatment decisions since about 1 in 5 women experience anxiety disorders during pregnancy or the postpartum period. Stopping medication abruptly can carry risks.
What the Study Found
Researchers led by Kelly Fung of Brigham and Women’s Hospital and Harvard Medical School analyzed data from two large U.S. databases, the Medicaid claims and the Merative MarketScan commercial claims database.
The analysis included more than 4 million pregnancies among women ages 12 to 55, and examined exposure to 13 benzodiazepines during the first trimester.
The pooled adjusted relative risk of congenital malformations was 0.99 (95% CI 0.96 to 1.03), which indicated no meaningful increase in risk.
In the Medicaid cohort malformation rates were 4.0% among pregnancies with benzodiazepine exposure and 4.1% among those without exposure. In the commercial cohort the rates were 4.9% and 4.8%.
Benzodiazepine exposure was found to be relatively uncommon. Filled prescriptions appeared in 2.1% of pregnancies in the Medicaid cohort and 1.6% in the commercial cohort.
Potential concerns include dependence misuse cognitive adverse effects and withdrawal. The American College of Obstetricians and Gynecologists recommends that patients and providers collaborate on treatment decisions when managing anxiety disorders during pregnancy.
Why Treatment Decisions Matter
People who develop benzodiazepine dependence must weigh medication related risks against the consequences of stopping treatment.
Long term use can lead to physical dependence, and abruptly stopping benzodiazepines can trigger severe withdrawal including seizures.
Pregnancy does not eliminate the need for a medically supervised taper when one is appropriate. Untreated anxiety can also complicate recovery especially among people with a history of substance use.
Patients should discuss benzodiazepine use during pregnancy and other life changes with a qualified prescriber who understands their medical history.
The Risks That Remain
The study had important limitations. Researchers included only live births so they did not assess miscarriage or other fetal losses. A filled prescription also does not confirm that someone took the medication.
The researchers called for further studies on miscarriage preterm birth and newborn outcomes including possible withdrawal symptoms in newborns.
These limitations do not negate the study’s findings on congenital malformations but they highlight the need for individualized treatment decisions and coordinated care.
The results offer reassurance about one potential risk but do not establish that benzodiazepines are safe in every circumstance.
Exploring Treatment Options
Anxiety and benzodiazepine use can occur together and treatment can address both concerns.
Rehab.com helps people compare providers that offer evidence based anxiety and addiction treatment, check insurance coverage and explore care options from outpatient therapy to medically supervised detox. Call
800-985-8516
( 
Sponsored Helpline )
to discuss treatment options with a treatment advisor.
